Literature DB >> 4574047

Infantile Hodgkin's disease: remission after measles.

H C Mota.   

Abstract

Entities:  

Mesh：

Year:  1973        PMID： 4574047      PMCID： PMC1589969          DOI： 10.1136/bmj.2.5863.421

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  1 in total

1.  Hodgkin's disease: remissions after measles.

Authors:  Z Zygiert
Journal:  Lancet       Date:  1971-03-20       Impact factor: 79.321
  1 in total
  12 in total

1.  Transient disappearance of immunologic disorders and remission after intercurrent measles infections in children with chronic idiopathic thrombocytopenic purpura.

Authors:  C Y Lin; M T Lin; Y L Hsieh; L Y Tsao
Journal:  J Clin Immunol       Date:  1988-05       Impact factor: 8.317

Review 2.  Attenuated oncolytic measles virus strains as cancer therapeutics.

Authors:  P Msaouel; I D Iankov; A Dispenzieri; E Galanis
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

Review 3.  Oncolytic measles virus strains as novel anticancer agents.

Authors:  Pavlos Msaouel; Mateusz Opyrchal; Evidio Domingo Musibay; Evanthia Galanis
Journal:  Expert Opin Biol Ther       Date:  2013-01-06       Impact factor: 4.388

Review 4.  Measles virus for cancer therapy.

Authors:  S J Russell; K W Peng
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

Review 5.  Relevance of the Measles Virus Expression in Cancer - an Update.

Authors:  Daniel Benharroch; Samuel Ariad; Noa Tadmor; Karen Nalbandyan; Irena Lazarev
Journal:  Pathol Oncol Res       Date:  2016-06-10       Impact factor: 3.201

Review 6.  Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.

Authors:  Pavlos Msaouel; Angela Dispenzieri; Evanthia Galanis
Journal:  Curr Opin Mol Ther       Date:  2009-02

7.  Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.

Authors:  Evanthia Galanis; Lynn C Hartmann; William A Cliby; Harry J Long; Prema P Peethambaram; Brigitte A Barrette; Judith S Kaur; Paul J Haluska; Ileana Aderca; Paula J Zollman; Jeff A Sloan; Gary Keeney; Pamela J Atherton; Karl C Podratz; Sean C Dowdy; C Robert Stanhope; Timothy O Wilson; Mark J Federspiel; Kah-Whye Peng; Stephen J Russell
Journal:  Cancer Res       Date:  2010-01-26       Impact factor: 12.701

8.  Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus.

Authors:  Ryan S Noyce; Daniel G Bondre; Michael N Ha; Liang-Tzung Lin; Gary Sisson; Ming-Sound Tsao; Christopher D Richardson
Journal:  PLoS Pathog       Date:  2011-08-25       Impact factor: 6.823

Review 9.  Does the measles virus contribute to carcinogenesis? - a review.

Authors:  Daniel Benharroch; Jacob Gopas; Samuel Ariad
Journal:  J Cancer       Date:  2014-01-05       Impact factor: 4.207

10.  Enhanced susceptibility of B lymphoma cells to measles virus by Epstein-Barr virus type III latency that upregulates CD150/signaling lymphocytic activation molecule.

Authors:  Satoshi Takeda; Daiki Kanbayashi; Takako Kurata; Hironori Yoshiyama; Jun Komano
Journal:  Cancer Sci       Date:  2014-01-12       Impact factor: 6.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.